Retatrutide | search
Click here to view Retatrutide news from 60+ newspapers.
Bookmark or Share- Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A ...Retatrutide (LY3437943) is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors. Its dose–response relationships with...
- Retatrutide: A Powerful New Weight Loss and Diabetes DrugRetatrutide helps address obesity and type 2 diabetes by stimulating insulin release and reducing the release of glucagon (a hormone that increases blood sugar). With more insulin in the blood and less glucagon, blood sugar levels drop, which supports weight loss.
- Lilly's phase 2 retatrutide results published in The New ...Lilly's phase 2 retatrutide results published in The New England Journal of Medicine show the investigational molecule achieved up to 17.5% mean weight reduction at 24 weeks in adults with obesity and overweight.
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A ...Background: Retatrutide (LY3437943) is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors. Its dose-response relationships with respect to side effects, safety, and efficacy for the treatment of obesity are not known.
- Triple hormone receptor agonist retatrutide for metabolic ...Retatrutide is a novel triple agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1 and glucagon receptors. A 48-week phase 2 obesity study...
More
